Towards personalized medicine in antifungal treatmentcombination of pharmacogenetics and pharmacokinetics

  1. Blanco Dorado, Sara
Dirixida por:
  1. M.ª Jesús Lamas Díaz Director
  2. Manuel Campos Toimil Director
  3. Anxo Fernández Ferreiro Director

Universidade de defensa: Universidade de Santiago de Compostela

Fecha de defensa: 05 de xuño de 2020

Tribunal:
  1. Olga Delgado Sánchez Presidente/a
  2. Arturo González Quintela Secretario
  3. Fernando Gutiérrez Nicolás Vogal
Departamento:
  1. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica

Tipo: Tese

Teseo: 629221 DIALNET lock_openMINERVA editor

Resumo

Voriconazole is an antifungal agent used in aspergillosis and in fluconazole-resistant Candida spp. infections. Voriconazol is mainly metabolized by cytochrome 2C19 wich is highly polymorphic. A significant portion of patients fail to achieve therapeutic drug concentrations, with a consequently increased risk of therapeutic failure. In this work, the use of voriconazole in the real life clinical setting was studied and a HPLC method for the pharmacokinetic determination of voriconazole was developed. In addition, the factors of voriconazole pharmacokinetic variability were evaluated demonstrating the importance of CYP2C19 pharmacogenetics and pharmacokinetic drug-drug interactions.